These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 17461889)

  • 21. Piracetam and levetiracetam: close structural similarities but different pharmacological and clinical profiles.
    Genton P; Van Vleymen B
    Epileptic Disord; 2000 Jun; 2(2):99-105. PubMed ID: 10954241
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Improved seizure control by alternating therapy of levetiracetam and valproate in epileptic rats.
    van Vliet EA; Edelbroek PM; Gorter JA
    Epilepsia; 2010 Mar; 51(3):362-70. PubMed ID: 19674045
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of levetiracetam, a novel antiepileptic drug, on convulsant activity in two genetic rat models of epilepsy.
    Gower AJ; Hirsch E; Boehrer A; Noyer M; Marescaux C
    Epilepsy Res; 1995 Nov; 22(3):207-13. PubMed ID: 8991787
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of levetiracetam on penicillin induced epileptic activity in rats.
    Arık AE; Bağırıcı F; Sefil F; Marangoz C
    Acta Neurobiol Exp (Wars); 2014; 74(3):266-75. PubMed ID: 25231846
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of levetiracetam on epileptiform discharges in human neocortical slices.
    Gorji A; Höhling JM; Madeja M; Straub H; Köhling R; Tuxhorn I; Ebner A; Wolf P; Panneck HW; Behne F; Lahl R; Speckmann EJ
    Epilepsia; 2002 Dec; 43(12):1480-7. PubMed ID: 12460248
    [TBL] [Abstract][Full Text] [Related]  

  • 26. No major role of common SV2A variation for predisposition or levetiracetam response in epilepsy.
    Lynch JM; Tate SK; Kinirons P; Weale ME; Cavalleri GL; Depondt C; Murphy K; O'Rourke D; Doherty CP; Shianna KV; Wood NW; Sander JW; Delanty N; Goldstein DB; Sisodiya SM
    Epilepsy Res; 2009 Jan; 83(1):44-51. PubMed ID: 18977120
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders.
    Malykh AG; Sadaie MR
    Drugs; 2010 Feb; 70(3):287-312. PubMed ID: 20166767
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Levetiracetam in children with refractory epilepsy: lack of correlation between plasma concentration and efficacy.
    Giroux PC; Salas-Prato M; Théorêt Y; Carmant L
    Seizure; 2009 Oct; 18(8):559-63. PubMed ID: 19546014
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Proepileptic phenotype of SV2A-deficient mice is associated with reduced anticonvulsant efficacy of levetiracetam.
    Kaminski RM; Gillard M; Leclercq K; Hanon E; Lorent G; Dassesse D; Matagne A; Klitgaard H
    Epilepsia; 2009 Jul; 50(7):1729-40. PubMed ID: 19486357
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Review on Pharmacokinetics of Levetiracetam in Neonates.
    Agrawal A; Banergee A
    Curr Drug Metab; 2017 Oct; 18(8):727-734. PubMed ID: 28595534
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Levetiracetam Clinical Pharmacokinetic Monitoring in Pediatric Patients with Epilepsy.
    Tan J; Paquette V; Levine M; Ensom MHH
    Clin Pharmacokinet; 2017 Nov; 56(11):1267-1285. PubMed ID: 28353057
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Levetiracetam and felbamate interact both pharmacodynamically and pharmacokinetically: an isobolographic analysis in the mouse maximal electroshock model.
    Luszczki JJ; Andres-Mach MM; Ratnaraj N; Patsalos PN; Czuczwar SJ
    Epilepsia; 2007 Apr; 48(4):806-15. PubMed ID: 17284299
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The efficacy of levetiracetam for patients with supratentorial brain tumors.
    Yuan Y; Peizhi Z; Maling G; Wu L; Yunhe M; Xiang W; Qing M; Yanhui L; Ruofei L; Jiewen L
    J Clin Neurosci; 2015 Aug; 22(8):1227-31. PubMed ID: 26051171
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enhanced efficacy of anticonvulsants when combined with levetiracetam in soman-exposed rats.
    Myhrer T; Enger S; Jonassen M; Aas P
    Neurotoxicology; 2011 Dec; 32(6):923-30. PubMed ID: 21570999
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of mGlu
    Metcalf CS; Klein BD; Smith MD; Pruess T; Ceusters M; Lavreysen H; Pype S; Van Osselaer N; Twyman R; White HS
    Epilepsia; 2017 Mar; 58(3):484-493. PubMed ID: 28166368
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Short-term effect of levetiracetam monotherapy on haematological parameters in children with epilepsy: a prospective study.
    Dinopoulos A; Attilakos A; Paschalidou M; Tsirouda M; Garoufi A; Moustaki M; Siafakas N; Papaevangelou V
    Epilepsy Res; 2014 May; 108(4):820-3. PubMed ID: 24630047
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The antiepileptic drug levetiracetam selectively modifies kindling-induced alterations in gene expression in the temporal lobe of rats.
    Gu J; Lynch BA; Anderson D; Klitgaard H; Lu S; Elashoff M; Ebert U; Potschka H; Löscher W
    Eur J Neurosci; 2004 Jan; 19(2):334-45. PubMed ID: 14725628
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Characteristics and indications of levetiracetam].
    Herranz JL; Argumosa A
    Rev Neurol; 2002 Sep; 35 Suppl 1():S110-6. PubMed ID: 12373663
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The place of levetiracetam in the treatment of epilepsy.
    Leppik IE
    Epilepsia; 2001; 42 Suppl 4():44-5. PubMed ID: 11564126
    [No Abstract]   [Full Text] [Related]  

  • 40. [Effectiveness and tolerability of levetiracetam in 43 children and adolescents with epilepsy].
    Herranz JL; Rufo-Campos M; Arteaga R
    Rev Neurol; 2003 Dec 1-15; 37(11):1005-8. PubMed ID: 14669138
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.